查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太临床生物标记市场：分析与预测（2023-2033）
市场调查报告书
商品编码
1501633

亚太临床生物标记市场：分析与预测（2023-2033）

Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 53 Pages | 商品交期: 1-5个工作天内

价格

亚太临床生物标记市场规模预计将从 2023 年的 32.8 亿美元增至 2033 年的 79.5 亿美元，预测期内复合年增长率为 9.27%。

主要市场统计数据
预测期 2023-2033
2023年评估 32.8亿美元
2033年预测 79.5亿美元
复合年增长率 9.27%

由于生物技术的进步、医疗保健支出的增加以及对个人化医疗的兴趣日益浓厚，亚太地区临床生物标记市场正在迅速扩大。中国、日本和印度等国家处于领先地位，在研发方面投入大量资金并积极进行临床试验活动。癌症和心血管疾病等慢性病盛行率的上升推动了对早期诊断工具和标靶治疗的需求。政府的倡议以及学术机构和生物製药公司之间的合作也支持了市场的成长。此外，次世代定序和生物资讯学等尖端技术的整合正在增强新型生物标记的识别和检验，使亚太地区成为临床生物标记领域的重要中心。

本报告调查了亚太地区临床生物标记市场，包括市场和技术趋势、市场影响因素分析、市场规模趋势和预测、主要国家的详细分析、竞争格局以及主要企业概况。

目录

执行摘要

第一章 市场

第二章 市场范围

第三章调查方法

第四章市场概况

  • 精准医学中的临床生物标记方法
  • 临床生物标记的潜在市场规模
  • COVID-19 对临床生物标记市场的影响
  • 市场趋势
    • 将人工智慧融入生物标记发现
    • 生物标记在精准医学中的使用增加
    • 临床生物标记测试中使用的技术
    • 临床生物标记的发现使得疾病的早期诊断成为可能

第五章 区域

  • 概述
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 其他的

第六章市场：公司简介

  • 概述
  • BGI
  • Novogene Co., Ltd.
Product Code: BHP2153SS

Introduction to Asia-Pacific Clinical Biomarkers Market

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$3.28 Billion
2033 Forecast$7.95 Billion
CAGR9.27%

Market Introduction

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

Market Segmentation:

Segmentation 1: by Country

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

  • BGI
  • Novogene Co., Ltd.

Table of Contents

Executive Summary

1 Market

2 Market Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Data Sources
    • 3.1.1 Primary Data Source
    • 3.1.2 Secondary Data Sources
      • 3.1.2.1 Open Sources
  • 3.2 Market Estimation Model
  • 3.3 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Clinical Biomarkers Approaches in Precision Medicine
  • 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
  • 4.4 COVID-19 Impact on Clinical Biomarkers Market
    • 4.4.1 COVID-19 Impact on Market Size
  • 4.5 Market Trends
    • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
    • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
    • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
    • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

  • 5.1 Overview
  • 5.2 Asia-Pacific
    • 5.2.1 China
    • 5.2.2 India
    • 5.2.3 Japan
    • 5.2.4 South Korea
    • 5.2.5 Australia
    • 5.2.6 Rest-of-Asia-Pacific

6 Market - Company Profiles

  • 6.1 Overview
  • 6.2 BGI
    • 6.2.1 Company Overview
    • 6.2.2 Role of BGI in the Clinical Biomarkers Market
    • 6.2.3 Corporate Strategies
      • 6.2.3.1 Product Launch
    • 6.2.4 Analyst's Perspective
  • 6.3 Novogene Co., Ltd.
    • 6.3.1 Company Overview
    • 6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
    • 6.3.3 Analyst's Perspective

List of Figures

  • Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 2: Asia-Pacific Clinical Biomarkers Market Research Methodology
  • Figure 3: Primary Research Methodology
  • Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 6: Biomarkers Used in Various Clinical Areas
  • Figure 7: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
  • Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
  • Figure 10: Use of Clinical Biomarkers in Personalized Medicine
  • Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
  • Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
  • Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
  • Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
  • Figure 15: Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 16: Asia-Pacific Clinical Biomarkers Market (by Country), $Billion, 2022-2033
  • Figure 17: Asia-Pacific: Market Dynamics
  • Figure 18: China Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 19: India Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 20: Japan Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 21: South Korea Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 22: Australia Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 23: Rest-of-Asia-Pacific Clinical Biomarkers Market, $Billion, 2022-2033
  • Figure 24: Total Number of Companies Profiled
  • Figure 25: BGI: Service Portfolio
  • Figure 26: Novogene Co., Ltd.: Service Portfolio

List of Tables

  • Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
  • Table 2: List of Product/Service Offered and its Technology